scPharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting. Its product pipeline also includes scFurosemide, a loop diuretic for the management of edema in patients with decompensated heart failure; scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-517-0730
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees27
Next Earnings Date5/6/2019 (Estimated)
OptionableNot Optionable
Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions
What is Scpharmaceuticals' stock symbol?
Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."
How were Scpharmaceuticals' earnings last quarter?
Scpharmaceuticals Inc (NASDAQ:SCPH) issued its earnings results on Thursday, March, 21st. The company reported ($0.27) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.44) by $0.17. View Scpharmaceuticals' Earnings History.
When is Scpharmaceuticals' next earnings date?
What price target have analysts set for SCPH?
4 Wall Street analysts have issued 12-month target prices for Scpharmaceuticals' shares. Their forecasts range from $5.00 to $14.00. On average, they anticipate Scpharmaceuticals' stock price to reach $10.3333 in the next year. This suggests a possible upside of 260.0% from the stock's current price. View Analyst Price Targets for Scpharmaceuticals.
What is the consensus analysts' recommendation for Scpharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scpharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scpharmaceuticals.
Has Scpharmaceuticals been receiving favorable news coverage?
News articles about SCPH stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Scpharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Scpharmaceuticals' key competitors?
Some companies that are related to Scpharmaceuticals include Axovant Sciences (AXGT), Mersana Therapeutics (MRSN), Tyme Technologies (TYME), Galectin Therapeutics (GALT), Recro Pharma (REPH), MEI Pharma (MEIP), LifeVantage (LFVN), Ardelyx (ARDX), Marinus Pharmaceuticals (MRNS), Adamas Pharmaceuticals (ADMS), CELYAD SA/ADR (CYAD), Arbutus Biopharma (ABUS), Molecular Templates (MTEM), Synlogic (SYBX) and Aldeyra Therapeutics (ALDX).
What other stocks do shareholders of Scpharmaceuticals own?
Who are Scpharmaceuticals' key executives?
Scpharmaceuticals' management team includes the folowing people:
- Mr. John H. Tucker, Pres, CEO, CFO & Director (Age 56)
- Dr. Pieter Muntendam, Consultant (Age 61)
- Rachael Nokes, Principal Accounting Officer
- Katherine Taudvin, Director of Corp. Devel. & Investor Relations
When did Scpharmaceuticals IPO?
(SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.
Who are Scpharmaceuticals' major shareholders?
Which major investors are buying Scpharmaceuticals stock?
How do I buy shares of Scpharmaceuticals?
Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Scpharmaceuticals' stock price today?
One share of SCPH stock can currently be purchased for approximately $2.87.
How big of a company is Scpharmaceuticals?
Scpharmaceuticals has a market capitalization of $53.32 million. The company earns $-29,440,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Scpharmaceuticals employs 27 workers across the globe.
What is Scpharmaceuticals' official website?
How can I contact Scpharmaceuticals?
Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]
MarketBeat Community Rating for Scpharmaceuticals (NASDAQ SCPH)
MarketBeat's community ratings are surveys of what our community members think about Scpharmaceuticals and other stocks. Vote "Outperform" if you believe SCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
